Specifically, in high‐grade gliomas such as adult glioblastoma, anaplastic oligodendroglioma, pediatric glioblastoma, and diffuse intrinsic pontine glioblastoma (DIPG), increased NLGN3 expression is associated with increased tumor aggressiveness and poorer patient survival [45, 151, 152]. The gene discussed is NLGN3; the disease is central nervous system cancer.